Abbvie pulls plug on Swedish R&D partnership

Swedish biotech firm Bioarctic expresses its disappointment over Abbvie’s decision to terminate a collaborative partnership on potential Parkinson’s treatments.
Photo: Abbvie / PR
Photo: Abbvie / PR
by andreas lønstrup, translated by daniel pedersen

US-based Abbvie has decided to end a collaboration with Swedish biotech firm Bioartic on the latter’s portfolio of alpha-synuclein antibodies, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading